WHAT IS CLAIMED IS:

1. Use of a cyanobacterial biomass in the manufacture of a medicament for reducing the level of hepatitis B surface antigen (HBsAg) detectable in a subject suffering from chronic HBV infection, wherein the cyanobacterial biomass is derived from *Arthrospira maxima* FEM102 strain and is to be (1) administered at a dosage of at least 2.97 grams daily and (2) co-administered with an antiviral agent, and the medicament comprises a pharmaceutically acceptable excipient.

2. The use according to claim 1, wherein the subject suffers from insomnia associated with chronic HBV infection.

3. The use according to claim 1, wherein the subject suffers from liver fibrosis associated with chronic HBV infection.

4. The use according to claim 1, wherein the cyanobacterial biomass is formulated in a pharmaceutical composition, which comprises an effective amount of the cyanobacterial biomass.

5. The use according to claim 4, wherein the pharmaceutical composition is formulated into a solid dosage form.

6. The use according to claim 5, wherein the pharmaceutically acceptable excipient is silicon dioxide or a sucrose ester of fatty acid.

7. The use according to claim 4, wherein the effective amount is 2.97 grams to 20 grams per day.

8. The use according to claim 1, wherein the cyanobacterial biomass is to be administered daily for at least one month.

9. The use according to claim 1, wherein the cyanobacterial biomass is to be administered orally.